Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 300
- Registration Number
- NCT06037980
- Locations
- 🇮🇹
Humanitas Cancer Center, Milan, Italy
🇮🇹Azienda Ospedaliera Universitaria Pisa, Pisa, Italy
🇮🇹ASST Spedali Civili, Brescia, Italy
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT06029270
- Locations
- 🇺🇸
Oncology Associates PC, Omaha, Nebraska, United States
🇺🇸Kaiser Permanente Dublin, Dublin, California, United States
🇺🇸Kaiser Permanente-Fremont, Fremont, California, United States
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT06027268
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Margaret Gatti-Mays
- Target Recruit Count
- 42
- Registration Number
- NCT06026657
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 198
- Registration Number
- NCT06023862
- Locations
- 🇰🇷
Bundang Seoul National University Hospital, Seongnam-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei Health System, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06018883
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 57
- Registration Number
- NCT06019130
- Locations
- 🇩🇪
Department of Pediatric Oncology and Hematology, Charité University Medicine Berlin, Berlin, Germany
🇩🇪Uniklinik RWTH Aachen, Department of Internal Medicine, Aachen, Germany
🇩🇪Evangelisches Klinikum Bethel, Children's Hospital, Bielefeld, Germany
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06017284
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 28
- Registration Number
- NCT06017297
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Georgetown University
- Registration Number
- NCT06017323
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.